Company Overview and News

0
NNUTU / Royal Hawaiian Orchards, L.P. null

2018-07-19 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$U,R P(&]B:@T\/"],:6YE87)I>F5D(#$O3" Q [email protected]# O3R Q-34O12 Q,[email protected]#%LQ-3,@ M-3-=+TEN9F\@,34R(# @4B],[email protected]@.38O4')E=B [email protected],C V+U1Y<&4O6%)E9B][email protected],R Q73X^#[email protected]>1_Z5P&)J"]8%U .X
NNUTU

0
NNUTU / Royal Hawaiian Orchards, L.P. null

2018-07-19 sec.gov
nnutu20180411_corresp.htm
NNUTU

0
NNUTU / Royal Hawaiian Orchards, L.P. null

2018-07-19 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C4Y(# @;V)J#3P\+TQI;F5A')[email protected]*, T*)25%3T8-"B @(" @(" @( T*[email protected],"!O8FH-/#PO M0R Y-R]&:6QT97(O1FQA=&5$96-O9&4O22 Q,
NNUTU

0
NNUTU / Royal Hawaiian Orchards, L.P. null

2018-07-19 sec.gov
nnutu20180427_corresp.htm
NNUTU

139
My 'Ten Commandments' Of Investing

2018-07-11 seekingalpha
In this letter, I wish to share with you our investment strategy and summarize for you the logic behind our investment activities.
BAMGF NNUTU NNUTD CALL RAD AGO BAMKF BAM

45
NNUTU / Royal Hawaiian Orchards, L.P. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-21 fintel.io
Royal Hawaiian Orchards, L.P. (OTC:NNUTU) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 239,917 shares. Largest shareholders include John G Ullman & Associates Inc. Royal Hawaiian Orchards, L.P. (OTC:NNUTU) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size.
PRTO NNUTU GALPW GALE GALEW

2
NNUTU / Royal Hawaiian Orchards, L.P. / EBRAHIMI FARHAD FRED - SC 13D/A (Activist Investment)

2018-06-21 sec.gov
SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
NNUTU

4
NNUTU / Royal Hawaiian Orchards, L.P. / EBRAHIMI FARHAD FRED - SC 13D/A (Activist Investment)

2018-06-21 sec.gov
SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
NNUTU

2
NNUTU / Royal Hawaiian Orchards, L.P. / Royal Hawaiian Orchards, L.p. - SCHEDULE 13E3/A

2018-06-18 sec.gov
nnutu20180614_sc13e3a.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
NNUTU

2
NNUTU / Royal Hawaiian Orchards, L.P. FORM 15-12B

2018-06-18 sec.gov
nnutu20180618_1512b.htm
NNUTU

2
NNUTU / Royal Hawaiian Orchards, L.P. / Royal Hawaiian Orchards, L.p. - SCHEDULE 13E3/A

2018-06-12 sec.gov
nnutu20180611_sc13e3a.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
NNUTU

2
NNUTU / Royal Hawaiian Orchards, L.P. FORM 8-K (Current Report)

2018-06-11 sec.gov
nnutu20180611_8k.htm united stateS securities and exchange commission Washington, D.C. 20549
NNUTU

2
NNUTU / Royal Hawaiian Orchards, L.P. / Royal Hawaiian Orchards, L.p. - SCHEDULE 13E3/A

2018-05-31 sec.gov
nnutu20180531_sc13e3a.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
NNUTU

2
NNUTU / Royal Hawaiian Orchards, L.P. FORM 8-K (Current Report)

2018-05-29 sec.gov
nnutu20180528_8k.htm united stateS securities and exchange commission Washington, D.C. 20549
NNUTU

2
NNUTU / Royal Hawaiian Orchards, L.P. FORM 10-Q (Quarterly Report)

2018-05-15 sec.gov
nnutu20180331_10q.htm Table of Contents UNITED STATES
NNUTU

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 78028T100